The Oxford Parkinson's Disease Centre (OPDC) is a unique multidisciplinary research program at the University of Oxford. The OPDC was established in February 2010 and brings together internationally-renowned scientists who work on the genetics of Parkinson’s, the generation of cell and animal models, and the wiring of brain circuits which control movement, with clinical experts in the diagnosis and treatment of Parkinson’s.
Our world-class research centre works to understand the earliest events in the development of Parkinson’s with an ultimate view to target the molecular mechanisms of disease with neuroprotective therapies to prevent disease onset or delay progression.
Our program is focused on the molecular pathways to Parkinson’s in order to:
- Understand the progression of Parkinson’s
- Predict the onset of Parkinson’s
- Identify potential drug targets for Parkinson’s
- Develop new treatments that will prevent the development of Parkinson’s in at-risk individuals.
Watch the video below to learn more about OPDC's research:
Post-translational proteomics platform identifies neurite outgrowth impairments in Parkinson's disease GBA-N370S dopamine neurons.
Bogetofte H. et al, (2023), Cell Rep, 42
Impaired dopamine release in Parkinson’s disease
Cramb KML. et al, (2023), Brain
Identification of a possible proteomic biomarker in Parkinson's disease: discovery and replication in blood, brain and cerebrospinal fluid.
Winchester L. et al, (2023), Brain Commun, 5
Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects.
Krohn L. et al, (2022), Nat Commun, 13
Universal clinical Parkinson's disease axes identify a major influence of neuroinflammation.
Sandor C. et al, (2022), Genome Med, 14
Age at onset as stratifier in idiopathic Parkinson's disease - effect of ageing and polygenic risk score on clinical phenotypes.
Pavelka L. et al, (2022), NPJ Parkinsons Dis, 8